Article

Ear Drops Beat Oral Medications in Children With Tympanostomy-Tube Otorrhea

Author(s):

A new study suggests antibiotic-glucocorticoid ear drops are superior to oral medications in children who suffer from acute otorrhea following the insertion of tympanostomy tubes for recurrent ear infections.

A new study suggests antibiotic-glucocorticoid ear drops are superior to oral medications in children who suffer from acute otorrhea following the insertion of tympanostomy tubes for recurrent ear infections.

For their trial published Feb. 20, 2014, in The New England Journal of Medicine, Thijs van Dongen, MD, and colleagues in the Netherlands randomized children aged between 1-10 years with uncomplicated acute tympanostomy-tube otorrhea to the hydrocortisone—bacitracin–colistin ear drops, oral amoxicillin–clavulanate suspension, or an initial observational approach.

After 2 weeks, only 5% of the children who received the antibiotic-glucocorticoid ear drops still had otorrhea, compared to 44% of those who received oral antibiotics and 55% of those who underwent observation. In addition, the median duration of the initial episode of discharge from the ears was 4 days for children treated with the ear drops, versus 5 days for those who received oral antibiotics (P< 0.001) and 12 days for those assigned to initial observation (P< 0.001).

According to the authors, treatment-related adverse events were mild, and no complications of otitis media — including local cellulitis, perichondritis, mastoiditis, and intracranial complications &mdash; were reported at 2 weeks.

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Developing Risk Assessment Tools for Viruses in School
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.